<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02291354</url>
  </required_header>
  <id_info>
    <org_study_id>RIGS-Pectin-STC-2015</org_study_id>
    <nct_id>NCT02291354</nct_id>
  </id_info>
  <brief_title>Evaluating the Synergism of Soluble Dietary Fiber With Fecal Microbiota Transplantation in Slow Transit Constipation</brief_title>
  <official_title>A Randomized, Controlled Study of Synergism of Soluble Dietary Fiber With Fecal Microbiota Transplantation in Adult Patients With Slow Transit Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jinling Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jinling Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the synergism of Soluble Dietary Fiber with Fecal&#xD;
      Microbiota Transplantation in Adult Patients with Slow Transit Constipation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Constipation is a chronic disease estimated to affect about 10% - 15% of the worldwide&#xD;
      general population. Recent evidence in the literature and collected in our laboratory confirm&#xD;
      that constipation can be a consequence of intestinal dysbiosis, which may affect the motility&#xD;
      and metabolic environment of colon.&#xD;
&#xD;
      Fecal Microbiota Transplantation (FMT) is temporarily effective for patients with slow&#xD;
      transit constipation. However, the transplanted microflora cannot maintain for a long time.&#xD;
      Along with the gut microbiota returning to the original state, the symptoms relapse.&#xD;
&#xD;
      Pectin is a kind of soluble dietary fiber, producing short chain fatty acids (SCFAs) after a&#xD;
      series of fermentation by gut flora to supply the energy for epithelial cells, regulate&#xD;
      intestinal PH, promote intestinal motility and join effort in immune regulation with&#xD;
      intestinal lymphoid tissue. Therefore, we conceive that pectin could promote the colonization&#xD;
      of probiotics and reduce adhesion of pathogens.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients having on average three or more SCBMs/week</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of patients having on average three or more spontaneous, complete bowel movements (SCBMs) per week was evaluated at week 4 and 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bowel habit assessments</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients kept daily diaries about times of bowel movements each day, stool consistency, degree of straining severity during defecation, and degree of sensation of incompleteness of evacuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Constipation-related symptoms assessments</measure>
    <time_frame>12 weeks</time_frame>
    <description>Constipation-related symptoms were evaluated using the validated Patient Assessment of Constipation Symptoms (PAC-SYM) questionnaire at week 4 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-Life assessments</measure>
    <time_frame>12 weeks</time_frame>
    <description>Quality-of-Life was evaluated using the validated Patient Assessment of Constipation Quality of Life (PACQOL) self-report questionnaire at week 4 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic transit time measurements</measure>
    <time_frame>12 weeks</time_frame>
    <description>Colonic transit time (CTT) was measured at week 4 and 12 with the Metcalf method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage of laxatives or enemas as rescue medication</measure>
    <time_frame>12 weeks</time_frame>
    <description>If patients did not have a bowel movement for 3 or more consecutive days, they were permitted to take up to 20 g of Macrogol 4000 powder (Forlax). If ineffective, enema were used. Patients kept daily diaries about the rescue medication when used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adverse events include fever, diarrhea, abdominal pain, increased bloating, borborygmi, flatulence, nausea, vomiting, nasopharyngitis, and any other disorders.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Slow Transit Constipation</condition>
  <arm_group>
    <arm_group_label>FMT + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients allocated to control group will receive standard FMT, followed by placebo for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FMT + Pectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients allocated to experiment group will receive standard FMT, followed by 24g pectin each day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pectin</intervention_name>
    <description>Patients allocated to experiment group will receive 12 g pectin each day for 12 weeks.</description>
    <arm_group_label>FMT + Pectin</arm_group_label>
    <other_name>soluble dietary fiber</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients allocated to experiment group will receive 12 g maltodextrin each day for 12 weeks.</description>
    <arm_group_label>FMT + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fecal microbiota transplantation (FMT)</intervention_name>
    <description>Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.</description>
    <arm_group_label>FMT + Pectin</arm_group_label>
    <arm_group_label>FMT + Placebo</arm_group_label>
    <other_name>Fecal bacteriotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic constipation according to Rome III criteria, defined as two or fewer&#xD;
             spontaneous, complete bowel movements (SCBMs) per week for a minimum of 6 months;&#xD;
&#xD;
          -  Age â‰¥ 18 years;&#xD;
&#xD;
          -  BMI: 18.5-25 kg/m2;&#xD;
&#xD;
          -  Slow colonic transit confirmed by colonic transit test (colonic transit time (CTT) &gt;&#xD;
             48 hours);&#xD;
&#xD;
          -  Normal anorectal manometry, with no evidence of dyssynergia and confirmed ability to&#xD;
             expel rectal balloon;&#xD;
&#xD;
          -  No radiographic evidence of functional (i.e. pelvic floor dyssynergia) or anatomical&#xD;
             (i.e. significant rectocele and intussusception) impediment to the expulsion of the&#xD;
             radio-opaque contrast;&#xD;
&#xD;
          -  Disease duration &gt; 1 year;&#xD;
&#xD;
          -  Traditional treatment with dietary modification, laxatives (including osmotic and&#xD;
             stimulant laxatives), and biofeedback tried over the past 6 months without success;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bowel constipation due to innate factor (i.e. megacolon) or secondary interventions&#xD;
             (i.e. drugs, endocrine, metabolic, neurologic or psychologic disorders);&#xD;
&#xD;
          -  History or evidence of gastrointestinal diseases (i.e. obstruction, cancer,&#xD;
             inflammatory bowel diseases) ;&#xD;
&#xD;
          -  Previous abdominal surgery, except cholecystectomy, appendicectomy, tubal ligation and&#xD;
             cesarean section;&#xD;
&#xD;
          -  Previous proctological or perianal surgery;&#xD;
&#xD;
          -  A constipation condition meeting the Rome III criteria for IBS or functional abdominal&#xD;
             pain syndrome;&#xD;
&#xD;
          -  Pregnant or breast-feeding women;&#xD;
&#xD;
          -  Infection with enteric pathogen;&#xD;
&#xD;
          -  Usage of probiotics, prebiotics and/or synbiotics within the last month;&#xD;
&#xD;
          -  Usage of antibiotics and/or PPIs within the last 3 months;&#xD;
&#xD;
          -  Smoking or alcohol addiction within the last 3 months;&#xD;
&#xD;
          -  Uncontrolled hepatic, renal, cardiovascular, respiratory or psychiatric disease;&#xD;
&#xD;
          -  Disease or therapy with drugs (i.e. antidepressants, opioid narcotic analgesics,&#xD;
             anticholinergics, calcium antagonists, nitrates, antimuscarinics) that, in the opinion&#xD;
             of the investigator, could affect intestinal transit and microbiota.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ning Li, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Generay Surgery, Jinling hosptal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianfeng Gong, MD</last_name>
    <phone>+86-25-80860036</phone>
    <email>jinlingh_gongjf@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ning Li, MD</last_name>
    <phone>+86-25-80860089</phone>
    <email>jinlingh_lining@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Generay Surgery, Jinling hosptal, Medical School of Nanjing University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Li, MD</last_name>
      <phone>+86-25-80860089</phone>
      <email>jinlingh_lining@126.com</email>
    </contact>
    <investigator>
      <last_name>Jianfeng Gong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chao Ding, MD candidate</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hongliang Tian, PhD candidate</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaolong Ge, MD candidate</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>November 11, 2014</study_first_submitted>
  <study_first_submitted_qc>November 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jinling Hospital, China</investigator_affiliation>
    <investigator_full_name>Jianfeng Gong</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Fecal Microbiota Transplantation</keyword>
  <keyword>Soluble Dietary Fiber</keyword>
  <keyword>Slow Transit Constipation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

